Armata Pharmaceuticals
ARMP
22 hedge funds and large institutions have $1.35M invested in Armata Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.14% less ownership
Funds ownership: 3.42% → 3.28% (-0.14%)
4% less funds holding
Funds holding: 23 → 22 (-1)
34% less capital invested
Capital invested by funds: $2.06M → $1.35M (-$711K)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.94K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.59K |
| 3 |
JP Morgan Chase
New York
|
+$215 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$26 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$41.1K |
| 2 |
Millennium Management
New York
|
-$19K |
| 3 |
HF
HRT Financial
New York
|
-$16.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.82K |
| 5 |
BlackRock
New York
|
-$1.38K |
ARMP Hedge Fund Activity: Q2 2023 in Review
22 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q2 2023, worth a combined $1.35M — down 34% from $2.06M a quarter earlier.
Fund positioning in ARMP was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.94K. The largest seller was Ergoteles, exiting entirely with an estimated $41.1K sold.
- 22 institutional investors held Armata Pharmaceuticals (ARMP) as of Q2 2023, down from 23 in Q1 2023.
- Funds reported $1.35M of Armata Pharmaceuticals stock for Q2 2023, down 34% quarter-over-quarter.
- 2 funds opened new Armata Pharmaceuticals positions in Q2 2023 and 2 closed out, a net change of 0 holders.
- The largest Armata Pharmaceuticals buyer in Q2 2023 was Vanguard Group, an estimated $3.94K added.
- The largest Armata Pharmaceuticals seller in Q2 2023 was Ergoteles, an estimated $41.1K sold.
Based on aggregated 13F filings for Q2 2023.